Generic Bryhali Availability
Last updated on Apr 10, 2025.
Bryhali is a brand name of halobetasol topical, approved by the FDA in the following formulation(s):
BRYHALI (halobetasol propionate - lotion;topical)
-
Manufacturer: BAUSCH
Approval date: November 6, 2018
Strength(s): 0.01% [RLD]
Is there a generic version of Bryhali available?
No. There is currently no therapeutically equivalent version of Bryhali available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Bryhali. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Pharmaceutical formulations containing corticosteroids for topical administration
Patent 10,478,502
Issued: November 19, 2019
Inventor(s): Angel Arturo & Dow Gordon
Assignee(s): Dow Pharmaceutical Sciences, Inc.Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.
Patent expiration dates:
- November 2, 2031✓✓
- November 2, 2031
-
Pharmaceutical formulations containing corticosteroids for topical administration
Patent 11,839,656
Issued: December 12, 2023
Inventor(s): Angel; Arturo et al.
Assignee(s): Bausch Health Ireland Limited (Dublin, IE)Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.
Patent expiration dates:
- November 2, 2031✓
- November 2, 2031
-
Pharmaceutical formulations containing corticosteroids for topical administration
Patent 11,957,753
Issued: April 16, 2024
Inventor(s): Angel; Arturo et al.
Assignee(s): BAUSCH HEALTH IRELAND LIMITED (Dublin, IE)Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.
Patent expiration dates:
- November 2, 2031✓
- November 2, 2031
-
Pharmaceutical formulations containing corticosteroids for topical administration
Patent 11,986,527
Issued: May 21, 2024
Inventor(s): Angel; Arturo et al.
Assignee(s): BAUSCH HEALTH IRELAND LIMITED (Dublin, IE)Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.
Patent expiration dates:
- November 2, 2031✓
- November 2, 2031
-
Pharmaceutical formulations containing corticosteroids for topical administration
Patent 12,076,403
Issued: September 3, 2024
Inventor(s): Angel; Arturo et al.
Assignee(s): Bausch Health Ireland Limited (Dublin, IE)Pharmaceutical compositions for topical application to skin are provided. In some embodiments, the pharmaceutical compositions comprise a corticosteroid and further comprise a liquid oil component comprising one or more dicarboxylic acid esters and/or monocarboxylic acid esters.
Patent expiration dates:
- November 2, 2031✓
- November 2, 2031
-
Pharmaceutical formulations containing corticosteroids for topical administration
Patent 8,809,307
Issued: August 19, 2014
Inventor(s): Angel Arturo & Dow Gordon
Assignee(s): Dow Pharmaceutical Sciences, Inc.The potency of a topical corticosteroid in a pharmaceutical formulation is maintained even when the concentration of the corticosteroid is substantially reduced by providing the corticosteroid in a formulation containing a liquid oil component that includes a dicarboxylic acid ester and/or a monocarboxylic acid ester.
Patent expiration dates:
- November 2, 2031✓
- November 2, 2031
More about Bryhali (halobetasol topical)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: topical steroids
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.